| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/02/2008 | CN101155788A Crystal of 4(3h)-quinazolinone derivative |
| 04/02/2008 | CN101152574A Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |
| 04/02/2008 | CN101152573A Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |
| 04/02/2008 | CN101152565A Erythropoietin ameliorates chemotherapy-induced toxicity in vivo |
| 04/02/2008 | CN101152563A Combination therapy using trefoil peptides |
| 04/02/2008 | CN101152164A Anti-cicatrix externally used pad pasting containing anti-hypertrophy cell medicament and method for preparing the same |
| 04/02/2008 | CN101152163A Anti-cicatrix externally used pad pasting containing hormone medicament and method for preparing the same |
| 04/02/2008 | CN100378118C Pharmaceutical compositions having appetite suppressant activity |
| 04/02/2008 | CN100378108C Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
| 04/02/2008 | CN100378063C Novel compounds and medicinal use thereof |
| 04/02/2008 | CN100377745C Stabilized medicine preparation form with by porous kietyoite covering flavour |
| 04/02/2008 | CN100377744C Compound medicine for predicting ACEI pressure reducing medicine effect |
| 04/02/2008 | CN100377743C Process for the preparation of a nutrient formulation |
| 04/02/2008 | CN100377710C Aromatase inhibition to enhance assisted reproduction |
| 04/02/2008 | CN100377706C A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
| 04/01/2008 | US7351875 Using recombinant rodent which expresses Fc gamma RIIa receptor as tool in identifying modulators for treatment and prevention of arthritic and autoimmune disorders |
| 04/01/2008 | US7351747 Skin treatment for relief of itch |
| 04/01/2008 | US7351741 4-(4-chloro2-hydroxybenzoylamino)butyric acid or salts for delivering an agent that would otherwise be destroyed or rendered less effective by conditions encountered before the agent reaches its target zone |
| 04/01/2008 | US7351729 JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers |
| 04/01/2008 | US7351715 Unit dosage forms for the treatment of herpes simplex |
| 04/01/2008 | US7351694 Diagnosis of prostate cancer; genetic engineered protein |
| 04/01/2008 | US7351692 Method and composition for potentiating the antipyretic action of a nonopioid analgesic |
| 04/01/2008 | US7351531 Molecules capable of binding to telomere and the like and method with the use of the same |
| 04/01/2008 | US7351524 Diagnostics and therapeutics for macular degeneration-related disorders |
| 04/01/2008 | US7351407 Administering agents such as GW-8510, purvalanol A, roscovitine to inhibit expression, signaling or biological functions of connective tissue growth factor |
| 04/01/2008 | CA2471952C Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists |
| 04/01/2008 | CA2356240C Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications |
| 04/01/2008 | CA2356157C Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications |
| 04/01/2008 | CA2343299C Method for preventing or delaying catheter-based revascularization |
| 04/01/2008 | CA2339004C Antioxidant composition and method of treating diseases using same |
| 04/01/2008 | CA2299288C Non-steroidal antiinflammatory drug formulations for topical application to the skin |
| 04/01/2008 | CA2231176C Long active composition for rectal administration |
| 03/27/2008 | WO2008036954A1 Use of n- [5- [ [ [5- (1, 1-dimethylethyl) -2-oxazoyl] methyl] thio] -2-thiazolyl] -4-piperidinecarboxamide |
| 03/27/2008 | WO2008036846A2 Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis |
| 03/27/2008 | WO2008035823A1 Cell death inhibitor |
| 03/27/2008 | WO2008035692A1 Cancer cell identification marker and cancer cell proliferation inhibitor |
| 03/27/2008 | WO2008034815A1 Combination of nmda- receptor ligand and a compound with 5-ht6 receptor affinity |
| 03/27/2008 | WO2008034244A1 The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases |
| 03/27/2008 | WO2008006895A3 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators |
| 03/27/2008 | WO2008005686A3 Compositions comprising a dissociated glucocorticoid receptor agonist and an immunosuppressive agent for treating dry eye |
| 03/27/2008 | WO2007089318A3 Compositions and methods for reducing food cravings |
| 03/27/2008 | WO2007088046A3 Nutritional system and methods for increasing longevity |
| 03/27/2008 | WO2007057508A3 Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol |
| 03/27/2008 | WO2004066943A3 Methods for diagnosis anf monitoring of neurological disease by detection of an encephalotoxin |
| 03/27/2008 | US20080077252 Muscle-Based Grafts/Implants |
| 03/27/2008 | US20080076835 Identifying modulator of silent information regulator 2 (Sir2) protein for use in transcriptional silencing and DNA damage repair; NAD and an acetylated histone peptide; cancer, neurodegenerative disorders, metabolic disorders, and disorders associated with apoptosis |
| 03/27/2008 | US20080076817 Neurotrophic N-glyoxyl-prolyl ester compounds e.g. 3-phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-pyrrolidinecarboxylate; non-immunosuppressive; side effect reduction; neurodegenerative diseases |
| 03/27/2008 | US20080076796 Methods and Compositions for the Treatment of Alcoholism and Alcohol Dependence |
| 03/27/2008 | US20080076757 Medicine for treating gastrointestinal disorder including irritable bowel syndrome |
| 03/27/2008 | US20080076704 Delivering therapeutic formulation containing N-sulphated-N,O-carboxymethylchitosan as a primary carrier across a membrane that has limited permeability for therapeutic agent |
| 03/27/2008 | US20080076702 synergistic coagulants comprising the mixture of a preparation of Blood Factor VII or related polypeptide and a preparation of factor VIII (antihemophilic factor) or related polypeptide; high speed coagulants in one dosage form; kits; hemostatic agents |
| 03/27/2008 | US20080076146 Harvesting, separating, culturing and exposing tissue to antiproliferative agents, monitoring variation in tissue propagation; immunotherapeutics; wound healing agents |
| 03/27/2008 | US20080076136 Nucleotide sequences coding transport protein for use in identifying modulators for treatment of pain; flavor enhancement |
| 03/27/2008 | US20080075773 Solid oral composition comprising 3-(5-methoxy-1H-indol-3-yl-methylene)-N-pentylcarbazimidamide or salt and disintegrant comprising crospovidone, sodium starch glycolate, carboxymethylcellulose sodium, sodium alginate; for administering active agents which are poorly soluble in water or acid sensitive |
| 03/27/2008 | US20080075729 ras-mediated; administering immunosuppressive for immune constituents that may interfere with the systemic delivery of the reovirus; antiproliferative; in the neoplastic cells phosphorylation of PKR is prevented by inactivation or deletion of PKR; antitumor agents |
| 03/27/2008 | US20080075719 Method for Augmenting B Cell Depletion |
| 03/27/2008 | US20080075713 isomerase enzymes and ATP-binding cassette (ABC) transport proteins, used for controlling metabolism of triglycerides; diagnosis, prevention and treatment of metabolic disorders |
| 03/27/2008 | US20080075711 used in the treatment or prophylaxis of bleeding episodes, coagulation disorders and maintain or enhance haemostasis; blood disorders |
| 03/27/2008 | US20080075691 Permucosal Composition and Method of Improving Permucosal Absorption |
| 03/27/2008 | DE102006046411A1 Arzneimittel zur Prophylaxe oder Behandlung oder Diagnostik von akutem Lungenversagen (ALI) Drugs for the prophylaxis or treatment or diagnosis of acute lung injury (ALI) |
| 03/27/2008 | DE102006046410A1 Arzneimittel zur Prophylaxe oder Behandlung oder Diagnostik von ischämischen Krankheiten Drugs for the prophylaxis or treatment or diagnosis of ischemic diseases |
| 03/27/2008 | DE102006045388A1 Topical dermatological preparations, for cosmetic or medicinal use, e.g. in moisturizing skin, contain active agent stored in multilamellar layers of hydrogenated liposomes |
| 03/27/2008 | CA2664421A1 Hmg coa reductase mediated modulation of neurogenesis |
| 03/27/2008 | CA2663347A1 Ppar mediated modulation of neurogenesis |
| 03/27/2008 | CA2663269A1 Combination of nmda-receptor ligand and a compound with 5-ht6 receptor affinity |
| 03/26/2008 | EP1903068A1 Biodegradable poly(beta-amino esters) and uses thereof |
| 03/26/2008 | EP1903057A2 Lipoprotein-regulating medicaments |
| 03/26/2008 | EP1902733A1 Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity |
| 03/26/2008 | EP1902732A1 Prophylactic/therapeutic agent for her2-expressing cancer |
| 03/26/2008 | EP1902731A1 Preventive or remedy for glaucoma |
| 03/26/2008 | EP1902730A1 Npy y2 agonist for use as therapeutic agent for disease accompanied by diarrhea |
| 03/26/2008 | EP1902729A1 Int6 PROTEIN INVOLVED IN HYPOXIA STRESS INDUCTION AND USE THEREOF |
| 03/26/2008 | EP1902718A1 Active foam |
| 03/26/2008 | EP1902714A1 Prodrugs of gaba analogs, compositions and uses thereof |
| 03/26/2008 | EP1901776A1 Novel medicinal combinations which are used for treating respiratory tract diseases and contain beta-2 long-acting agonists and at least one other type of active substance |
| 03/26/2008 | EP1901775A2 Kinin antagonists for treating bladder dysfunction |
| 03/26/2008 | EP1901767A2 Methods and systems for neural maintenance and regeneration |
| 03/26/2008 | EP1901765A1 Intralesional treatment of psoriasis |
| 03/26/2008 | EP1901753A1 Multiple sclerosis therapy and diagnosis |
| 03/26/2008 | EP1901738A1 Wortmannin analogs and methods of using same in combination with chemotherapeutic agents |
| 03/26/2008 | EP1817039A4 Treatment and prevention of epilepsy |
| 03/26/2008 | EP1747017B1 Use of targeted oxidative therapeutic formulation in treatment of age-related macular degeneration |
| 03/26/2008 | EP1673107B1 Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker |
| 03/26/2008 | EP1585497B1 Mastitis treatment with a combination of prednisolon and cephalosporin |
| 03/26/2008 | EP1465911B1 Compositions and methods for diagnosing and treating diabetes, insulin resistance and dyslipidemia |
| 03/26/2008 | EP1458866B1 Modified tridegins, production and use thereof as transglutaminase inhibitors |
| 03/26/2008 | EP1448784B1 Antibiotics ge 81112 factors a, b, b1, pharmaceutically acceptable salts and compositions, and use thereof |
| 03/26/2008 | EP1339373B1 Use of moulding compounds for producing treatment devices |
| 03/26/2008 | EP1248847B1 Irak-4: compositions and methods of use |
| 03/26/2008 | EP1229918B1 Pharmaceutical composition comprising a combination of metformin and glibenclamide |
| 03/26/2008 | EP1140042B1 Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites |
| 03/26/2008 | EP0917535B1 Neuroactive peptide |
| 03/26/2008 | CN101151274A ROR alpha for promoting the induction of Bmal1 expression |
| 03/26/2008 | CN101151051A Analgesic combination of sodium channel blockers with opioid antagonists |
| 03/26/2008 | CN101151050A Agent for control of degranulation reaction and cytokine production |
| 03/26/2008 | CN101151046A Anti-viral agent |
| 03/26/2008 | CN101151018A Ophthalmologic compositions and use mode thereof |
| 03/26/2008 | CN101147741A Medicine for giving up drug |
| 03/26/2008 | CN101147734A Compositions and method for treating infection |
| 03/26/2008 | CN100376288C Improvement of T cell mediated immunity |